Clinical-stage biotechnology company developing IP-001, a proprietary immune-modulating glycan/carbohydrate polymer intended to turn routine tumor ablation into systemic cancer immunotherapy
Clinical-stage biotechnology company developing IP-001, a proprietary immune-modulating glycan/carbohydrate polymer intended to turn routine tumor ablation into systemic cancer immunotherapy. Its platform aims to enhance tumor-antigen capture and immune activation, including T-cell responses, for solid-tumor cancers; the company is also exploring applications in infectious diseases.